Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer

被引：0
|
作者：
Han, S. [1 ]
Kwak, K. [1 ]
Kim, J. [1 ]
Kim, J. [1 ]
Park, K. [1 ]
机构：
[1] Inje Univ, Sanggye Paik Hosp, Breast Canc Ctr, Seoul, South Korea
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
    Iwata, Hiroji
    Sato, Nobuaki
    Masuda, Norikazu
    Nakamura, Seigo
    Yamamoto, Naohito
    Kuroi, Katsumasa
    Kurosumi, Masafumi
    Tsuda, Hitoshi
    Akiyama, Futoshi
    Ohashi, Yasuo
    Toi, Masakazu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (07) : 867 - 875
  • [2] Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
    Zhang, Minmin
    Wei, Wei
    Liu, Jianlun
    Yang, Huawei
    Jiang, Yi
    Tang, Wei
    Li, Qiuyun
    Liao, Xiaoming
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3443 - 3450
  • [3] Clinical Comparison of Safety and Efficacy of Vinorelbine/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC)
    Yan, Peng-Wei
    Huang, Xin-En
    Jiang, Yong
    Tang, Jin-Hai
    Xu, Hong-xia
    Xu, Xia
    Jin, Xiang
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (04) : 1115 - 1118
  • [4] Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
    Puerto, VL
    Cardenas, J
    Lara, F
    Goana, R
    Silva, A
    Barroso, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 299 - 299
  • [5] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
    Boccardo, Francesco
    Amadori, Dino
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    [J]. ONCOLOGY, 2010, 78 (3-4) : 274 - 281
  • [6] Combination of vinorelbine, epirubicin, and cyclophosphamide as Neoadjuvant chemotherapy for locally advanced breast cancer - Phase II study
    Braud, AC
    Levy, E
    Feuilhade, F
    Otmezguine, Y
    Calitchi, E
    Kirova, Y
    Le Bourgeois, JP
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (03): : 303 - 307
  • [7] Prospective randomized study of neoadjuvant chemotherapy (NACT) with paclitaxel/epirubicin (PE) versus fluorouracil/epirubicin/cyclophosphamide (FEC) in operable stage II-IIIA breast cancer (BC)
    Malamos, N
    Kosmas, C
    Antonopoulos, MJ
    Tsikkinis, A
    Pallis, L
    Papadiamantis, J
    Kouri, E
    Vasilaros, S
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 22 - 23
  • [8] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    [J]. TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
  • [9] Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as Neoadjuvant treatment in 89 patients with operable breast cancer
    Van Praagh, I
    Cure, H
    Leduc, B
    Charrier, S
    Le Bouedec, G
    Achard, JL
    Ferriere, JP
    Feillel, V
    De Latour, M
    Dauplat, J
    Chollet, P
    [J]. ONCOLOGIST, 2002, 7 (05): : 418 - 423
  • [10] Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer
    Abrial, C
    Van Praagh, I
    Delva, R
    Leduc, B
    Fleury, J
    Gamelin, E
    Sillet-Bach, I
    Penault-Llorca, F
    Amat, S
    Chollet, P
    [J]. ONCOLOGIST, 2005, 10 (04): : 242 - 249
12345